The c.-133A > G polymorphism in NPC1L1 gene influences the efficacy of ezetimibe monotherapy on apolipoprotein A1 in hyperlipidemic patients.
Zsíros, N; Bodor, M; Varga, V; Berta, E; Balogh, I; Seres, I; Paragh, G; Harangi, M.
; 69(6): 424-9, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24974575
Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia.
Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.
Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice.
Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients.
Should an LDL-Cholesterol Target-Based Approach Be Readopted?
Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.
Kombinovaná hypolipidemická léčba.
The effect of ezetimibe monotheraphy on mean platelet volume in patients with hyperlipidaemia: a retrospective study of 45 patients.
Effect of apolipoprotein E genotypes on the efficacy of ezetimibe monotherapy in patients with statin induced adverse effects.
Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe.